Ad
Tuesday, 6 December 2016
AstraZeneca pill slashes lung cancer progression in study
LONDON (Reuters) - AstraZeneca's pill Tagrisso cut the risk of lung cancer progressing by 70 percent compared to standard chemotherapy in a major clinical trial, lifting prospects for a drug that is key to the company's ambitious long-term sales goals.
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment